Despite the positive outcomes, the study's retrospective nature and absence of a control group highlight the necessity for larger, prospective trials.<h4>Conclusion</h4>GLP-1 agonists show considerable potential in the management of type 1 diabetes by protecting residual beta cells, promoting cell proliferation, and reprogramming hepatic cells. This evidence concerns the gene GCG and type 1 diabetes mellitus.